Table 2.
Characters | FC-score | |||
---|---|---|---|---|
0 | 1 | 2 | P-value | |
all patients | 386 | 176 | 54 | |
Gender, male/female | 66/320 | 30/146 | 6/48 | 0.53 |
Age, <60/≥60 | 220/166 | 89/87 | 34/20 | 0.193 |
HBsAg, | ||||
negative/positive | 53/333 | 40/136 | 7/47 | 0.022 |
AFP | ||||
<400/≥400 ng/mL | 282/104 | 123/53 | 30/24 | 0.029 |
TBIL | ||||
<20/≥20 µmol/L | 352/34 | 162/14 | 44/10 | 0.05 |
GGT, <45/≥45 U/L | 178/208 | 61/115 | 9/45 | <0.001 |
ALT, <50/≥50 U/L | 304/82 | 148/28 | 43/11 | 0.333 |
ALB, <35/≥35g/L | 12/374 | 3/173 | 6/48 | 0.003 |
CRP, <10/≥10mg/L | 386/0 | 163/13 | 0/54 | <0.001 |
PLT | ||||
<200/≥200 10^9/L | 341/45 | 136/40 | 32/22 | <0.001 |
N,<6.3/≥6.3 10^9/L | 353/33 | 161/15 | 38/16 | <0.001 |
L,<3.2/≥3.2 10^9/L | 371/15 | 160/16 | 49/5 | 0.027 |
M,<0.6/≥0.6 10^9/L | 311/75 | 114/62 | 14/40 | <0.001 |
cirrhosis,no/yes | 72/314 | 61/115 | 23/31 | <0.001 |
tumor number, | ||||
single/multiple | 340/46 | 144/32 | 49/5 | 0.083 |
tumor throbus | ||||
no/yes | 373/13 | 162/14 | 42/12 | <0.001 |
tumor capsule | ||||
no/yes | 260/126 | 103/73 | 31/23 | 0.074 |
tumor size | ||||
<5/≥5cm | 266/120 | 83/93 | 11/43 | <0.001 |
LNM | ||||
no/yes | 384/2 | 176/0 | 52/2 | 0.011 |
MVI, no/yes | 303/83 | 120/56 | 27/27 | <0.001 |
differentiation, | ||||
I-II/III-IV | 271/115 | 119/57 | 31/23 | 0.161 |
IBS, 0/1 | 219/167 | 82/94 | 21/33 | 0.005 |
GPS, 0/1/2 | 367/19/0 | 163/11/2 | 5/43/6 | <0.001 |
IBI,0/1/2 | 12/374/0 | 1/166/89 | 0/11/43 | <0.001 |
FC-score,0/1/2 | ||||
BCLC, A/B/C | 301/74/11 | 93/72/12 | 8/40/6 | <0.001 |
CLIP, 0/1-3/4-6 | 235/150/1 | 85/90/1 | 17/32/5 | <0.001 |
APF, alpha fetal protein; FIB, fibrinogen; PLT, platelet; LNM, lymph node metastasis; MVI, microvascular invasion; IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.